Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: WeirdPro Randy who wrote (1006)	2/1/1998 12:25:00 PM
From: NeuroInvestment	Respond to of 1359

Perhaps I was unclear in an earlier post; the Redux II study was double-blinded, placebo-controlled....and it is correct that it may shed significant light upon implications of short-duration Redux usage, which constituted the great majority of Redux use. It will not say anything about longer-duration use. I was simply being cautionary about overvaluing rumors about what the study is showing; the great advantage to the three studies that will come out over the next three months is that we will finally have some high quality data; the first time this has occurred in this whole fluramine usage issue. NeuroInvestment (www.neuroinv.com)